Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vimizim in Australian Patients With MPS IVA
NCT01966029Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jul 2013
- Primary completion
- Jul 2016
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elosulfase alfa in mucopolysaccharidosis type IVA, sponsored by BioMarin Pharmaceutical. Primary endpoint: Safety Analysis (AEs and SAEs). Started Jul 2013; status: completed.
02
Drugs
elosulfase alfa
03
Conditions
mucopolysaccharidosis type IVA
Beyond the preview
Go deeper on NCT01966029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01966029.